LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 23.0
(0.88%)
TWD 23.0
(0.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 834.17 Million TWD | 3.5% |
| 2022 | 805.92 Million TWD | -14.98% |
| 2021 | 947.89 Million TWD | -5.53% |
| 2020 | 1 Billion TWD | -11.52% |
| 2019 | 1.13 Billion TWD | 6.8% |
| 2018 | 1.06 Billion TWD | -33.87% |
| 2017 | 1.6 Billion TWD | -7.49% |
| 2016 | 1.73 Billion TWD | 4.62% |
| 2015 | 1.65 Billion TWD | -13.42% |
| 2014 | 1.91 Billion TWD | -10.56% |
| 2013 | 2.14 Billion TWD | 44.52% |
| 2012 | 1.48 Billion TWD | 19.98% |
| 2011 | 1.23 Billion TWD | 20.22% |
| 2010 | 1.02 Billion TWD | -16.72% |
| 2009 | 1.23 Billion TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 823.49 Million TWD | 1.97% |
| 2024 Q3 | 794.29 Million TWD | -3.55% |
| 2024 Q1 | 807.6 Million TWD | -3.18% |
| 2023 Q2 | 824.09 Million TWD | -0.47% |
| 2023 FY | 834.17 Million TWD | 3.5% |
| 2023 Q1 | 827.97 Million TWD | 2.74% |
| 2023 Q4 | 834.17 Million TWD | 3.66% |
| 2023 Q3 | 804.73 Million TWD | -2.35% |
| 2022 FY | 805.92 Million TWD | -14.98% |
| 2022 Q4 | 805.92 Million TWD | -0.25% |
| 2022 Q3 | 807.97 Million TWD | -3.51% |
| 2022 Q2 | 837.36 Million TWD | -9.07% |
| 2022 Q1 | 920.92 Million TWD | -2.85% |
| 2021 Q1 | 981.17 Million TWD | -2.21% |
| 2021 Q4 | 947.89 Million TWD | -2.95% |
| 2021 Q3 | 976.73 Million TWD | -13.28% |
| 2021 FY | 947.89 Million TWD | -5.53% |
| 2021 Q2 | 1.12 Billion TWD | 14.79% |
| 2020 FY | 1 Billion TWD | -11.52% |
| 2020 Q4 | 1 Billion TWD | -1.57% |
| 2020 Q3 | 1.01 Billion TWD | -0.88% |
| 2020 Q1 | 1.11 Billion TWD | -1.69% |
| 2020 Q2 | 1.02 Billion TWD | -7.76% |
| 2019 FY | 1.13 Billion TWD | 6.8% |
| 2019 Q4 | 1.13 Billion TWD | 8.26% |
| 2019 Q2 | 1.01 Billion TWD | -3.63% |
| 2019 Q1 | 1.05 Billion TWD | -0.44% |
| 2019 Q3 | 1.04 Billion TWD | 2.81% |
| 2018 Q3 | 1.33 Billion TWD | -5.41% |
| 2018 Q1 | 1.46 Billion TWD | -8.64% |
| 2018 FY | 1.06 Billion TWD | -33.87% |
| 2018 Q4 | 1.06 Billion TWD | -20.56% |
| 2018 Q2 | 1.41 Billion TWD | -3.67% |
| 2017 Q3 | 1.84 Billion TWD | 10.95% |
| 2017 Q2 | 1.66 Billion TWD | -5.41% |
| 2017 Q1 | 1.75 Billion TWD | 1.18% |
| 2017 FY | 1.6 Billion TWD | -7.49% |
| 2017 Q4 | 1.6 Billion TWD | -12.88% |
| 2016 Q1 | 1.51 Billion TWD | -8.85% |
| 2016 FY | 1.73 Billion TWD | 4.62% |
| 2016 Q4 | 1.73 Billion TWD | 7.32% |
| 2016 Q3 | 1.61 Billion TWD | 6.26% |
| 2016 Q2 | 1.52 Billion TWD | 0.66% |
| 2015 Q3 | 1.66 Billion TWD | -2.4% |
| 2015 Q4 | 1.65 Billion TWD | -0.35% |
| 2015 FY | 1.65 Billion TWD | -13.42% |
| 2015 Q1 | 1.85 Billion TWD | -3.25% |
| 2015 Q2 | 1.7 Billion TWD | -7.99% |
| 2014 Q1 | 1.92 Billion TWD | -10.21% |
| 2014 Q4 | 1.91 Billion TWD | -0.05% |
| 2014 FY | 1.91 Billion TWD | -10.56% |
| 2014 Q3 | 1.91 Billion TWD | -9.41% |
| 2014 Q2 | 2.11 Billion TWD | 10.02% |
| 2013 Q2 | 1.91 Billion TWD | 19.73% |
| 2013 Q4 | 2.14 Billion TWD | 6.49% |
| 2013 FY | 2.14 Billion TWD | 44.52% |
| 2013 Q1 | 1.6 Billion TWD | 8.1% |
| 2013 Q3 | 2.01 Billion TWD | 4.86% |
| 2012 Q4 | 1.48 Billion TWD | 20.65% |
| 2012 Q3 | 1.22 Billion TWD | -5.13% |
| 2012 FY | 1.48 Billion TWD | 19.98% |
| 2012 Q2 | 1.29 Billion TWD | -4.07% |
| 2012 Q1 | 1.34 Billion TWD | 9.27% |
| 2011 Q3 | 1.47 Billion TWD | 45.63% |
| 2011 Q4 | 1.23 Billion TWD | -16.51% |
| 2011 Q2 | 1.01 Billion TWD | -12.99% |
| 2011 Q1 | 1.16 Billion TWD | 13.63% |
| 2011 FY | 1.23 Billion TWD | 20.22% |
| 2010 FY | 1.02 Billion TWD | -16.72% |
| 2010 Q4 | 1.02 Billion TWD | 0.0% |
| 2009 FY | 1.23 Billion TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Grape King Bio Ltd | 15.51 Billion TWD | 94.622% |
| Standard Chem & Pharm CO., LTD. | 11.18 Billion TWD | 92.545% |
| Maywufa Company Ltd. | 2.83 Billion TWD | 70.545% |
| ScinoPharm Taiwan, Ltd. | 11.72 Billion TWD | 92.883% |
| Lotus Pharmaceutical Co., Ltd. | 32.99 Billion TWD | 97.472% |
| YungShin Global Holding Corporation | 11.51 Billion TWD | 92.754% |
| PhytoHealth Corporation | 2.35 Billion TWD | 64.511% |
| SCI Pharmtech, Inc. | 6.69 Billion TWD | 87.532% |
| Formosa Laboratories, Inc. | 13.63 Billion TWD | 93.883% |
| PharmaEssentia Corporation | 27.26 Billion TWD | 96.941% |
| Bora Pharmaceuticals Co., LTD. | 25.05 Billion TWD | 96.67% |